Anti-CTLA4 抗体 [BNI3] (ab19792)
Key features and details
- Mouse monoclonal [BNI3] to CTLA4
- Suitable for: IHC-Fr, IP, ICC/IF, Flow Cyt
- Reacts with: Human
- Isotype: IgG2a
Related conjugates and formulations
製品の概要
-
製品名
Anti-CTLA4 antibody [BNI3]
CTLA4 一次抗体 製品一覧 -
製品の詳細
Mouse monoclonal [BNI3] to CTLA4 -
由来種
Mouse -
特異性
IHC-P has been removed following customer feedback of no signal in this application. If you are looking for a CTLA4 antibody for use in IHC-P we would recommend our rabbit monoclonal ab227709 specifically designed for use in this application. -
アプリケーション
適用あり: IHC-Fr, IP, ICC/IF, Flow Cytmore details -
種交差性
交差種: Human -
免疫原
Recombinant full length protein corresponding to Human CTLA4. Human CTLA4 Recombinant Protein
-
ポジティブ・コントロール
- ICC/FACS: B cells
-
特記事項
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles. -
バッファー
pH: 7.20
Preservative: 0.09% Sodium azide
Constituents: 0.87% Sodium chloride, 0.14% Monobasic dihydrogen sodium phosphate -
Concentration information loading...
-
精製度
Affinity purified -
ポリ/モノ
モノクローナル -
クローン名
BNI3 -
ミエローマ
P3x63-Ag8.653 -
アイソタイプ
IgG2a -
研究分野
関連製品
-
Alternative Versions
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab19792の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
IHC-Fr |
Use at an assay dependent concentration.
|
|
IP |
Use at an assay dependent concentration.
|
|
ICC/IF |
Use at an assay dependent concentration.
|
|
Flow Cyt |
Use at an assay dependent concentration.
ab170191 - Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody. |
特記事項 |
---|
IHC-Fr
Use at an assay dependent concentration. |
IP
Use at an assay dependent concentration. |
ICC/IF
Use at an assay dependent concentration. |
Flow Cyt
Use at an assay dependent concentration. ab170191 - Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody. |
ターゲット情報
-
機能
Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. -
組織特異性
Widely expressed with highest levels in lymphoid tissues. Detected in activated T-cells where expression levels are 30- to 50-fold less than CD28, the stimulatory coreceptor, on the cell surface following activation. -
関連疾患
Genetic variation in CTLA4 influences susceptibility to systemic lupus erythematosus (SLE) [MIM:152700]. SLE is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue. It affects principally the skin, joints, kidneys and serosal membranes. SLE is thought to represent a failure of the regulatory mechanisms of the autoimmune system.
Note=Genetic variations in CTLA4 may influence susceptibility to Graves disease, an autoimmune disorder associated with overactivity of the thyroid gland and hyperthyroidism.
Genetic variation in CTLA4 is the cause of susceptibility to diabetes mellitus insulin-dependent type 12 (IDDM12) [MIM:601388]. A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.
Genetic variation in CTLA4 is the cause of susceptibility to celiac disease type 3 (CELIAC3) [MIM:609755]. It is a multifactorial disorder of the small intestine that is influenced by both environmental and genetic factors. It is characterized by malabsorption resulting from inflammatory injury to the mucosa of the small intestine after the ingestion of wheat gluten or related rye and barley proteins. In its classic form, celiac disease is characterized in children by malabsorption and failure to thrive. -
配列類似性
Contains 1 Ig-like V-type (immunoglobulin-like) domain. -
翻訳後修飾
N-glycosylation is important for dimerization.
Phosphorylation at Tyr-201 prevents binding to the AP-2 adapter complex, blocks endocytosis, and leads to retention of CTLA4 on the cell surface. -
細胞内局在
Cell membrane. Exists primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid internalisation and. - Information by UniProt
-
参照データベース
- Entrez Gene: 1493 Human
- Omim: 123890 Human
- SwissProt: P16410 Human
- Unigene: 247824 Human
-
別名
- ALPS5 antibody
- CD 152 antibody
- CD antibody
see all
プロトコール
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (8)
ab19792 は 8 報の論文で使用されています。
- Tiemann M et al. Identification of CTLA-4-Positive Cells in the Human Tonsil. Cells 10:N/A (2021). PubMed: 33925389
- Sánchez-Magraner L et al. High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment. Cancer Res 80:4244-4257 (2020). PubMed: 32855204
- de Souza TL et al. Pro-Cellular Exhaustion Markers are Associated with Splenic Microarchitecture Disorganization and Parasite Load in Dogs with Visceral Leishmaniasis. Sci Rep 9:12962 (2019). PubMed: 31506501
- Kümpers C et al. Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma. Front Med (Lausanne) 6:27 (2019). PubMed: 30931305
- Gulati N et al. Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions. F1000Res 4:149 (2015). PubMed: 26236467
- Mittal AK et al. Role of CTLA4 in the proliferation and survival of chronic lymphocytic leukemia. PLoS One 8:e70352 (2013). WB ; Human . PubMed: 23936412
- Suárez-Fariñas M et al. Expanding the Psoriasis Disease Profile: Interrogation of the Skin and Serum of Patients with Moderate-to-Severe Psoriasis. J Invest Dermatol : (2012). IHC-Fr ; Human . PubMed: 22763790
- Kozik P et al. A screen for endocytic motifs. Traffic 11:843-55 (2010). PubMed: 20214754